Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: February-01-10
Credit Expiration Date: February-01-11

Faculty

David S. Ettinger, MD (Chair)
Alex Grass Professor of Oncology
The Johns Hopkins University School of Medicine
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD

Jyoti D. Patel, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Feinberg School of Medicine
Northwestern University
Chicago, IL

Mark A. Socinski, MD
Professor of Medicine
Multidisciplinary Thoracic Oncology Program
Lineberger Comprehensive Cancer Center
University of North Carolina Chapel Hill
Chapel Hill, NC

Credit Hours

1

Medium

e-Monograph

Program Description

Lung cancer is the leading cause of worldwide cancer mortality and is responsible for more deaths annually in the United States than the combination of breast, colorectal, and prostate cancer. Almost 85% of lung cancers are classified as non-small cell lung cancer (NSCLC), and up to 40% of NSCLC present as locally advanced (stage III) or metastatic disease (stage IV). Although lung cancer has long been the leading cause of cancer death in men, it surpassed breast cancer as the leading cause of cancer death in women only relatively recently.

Significant gaps in knowledge exist regarding recent clinical data available to guide clinicians in the management of NSCLC. Treatment approaches based on personalized medicine, targeted therapies, and tumor histologies represent a significant advance in the treatment of NSCLC. There is a significant need to educate oncologists regarding molecular markers in the pathogenesis of NSCLC, as well as the role of histology in treatment response to various agents for patients with advanced NSCLC. This activity focuses on recent evidence and areas of promising investigation that will help increase knowledge, and improve and personalize the care for patients with NSCLC.


The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

Target Audience

This program is designed for oncologists, pathologists, and other healthcare professionals interested or involved in the treatment of patients with lung cancer. There are no prerequisites to participate in this activity.

Estimated amount of time to complete: 1 hour

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Evaluate recent trends in tailoring treatment decisions based on NSCLC histology.
  2. Individualize treatment regimens based on patient and/or tumor characteristics.
  3. Examine the role of maintenance/sequential therapy for patients with NSCLC.

Disclosures

Full Disclosure Policy Affecting CME Activities: As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:

David Ettinger: Consultant and Honoraria: AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Eisai, Genentech, GlaxoSmithKline, ImClone, Merck, Novartis, Pfizer, and sanofi-aventis.

Jyoti Patel: Consultant and Research Funding: Eli Lilly, Genentech.

Mark Socinski: Speakersí Bureau and Honoraria: Eli Lilly, Genentech; Research Funding: Abraxis Bioscience, Eli Lilly, Pfizer, Genentech, Celgene, Bristol-Myers Squibb.

Off-Label Discussions: This monograph references unlabelled/ unapproved uses of: erlotinib; combination therapies:
cetuximab + cisplatin/vinorelbine, erlotinib + bevacizumab.

Credit Statements

Accreditation Statement: The Johns Hopkins University School of Medicine is accredited by by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement: The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Commercial Support Statements

This continuing medical education activity is made possible by educational grants from Eli Lilly & Company and Genentech, Inc.

Certificate Fee

$0.00

Disclaimer

© 2010, The Johns Hopkins University School of Medicine. All Rights Reserved. The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of the Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS